Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration | ||
By: PR Newswire Association LLC. - 13 Feb 2019 | Back to overview list |
|
SAN DIEGO, Feb. 13, 2019 /PRNewswire/ -- Abilita Bio, Inc. announced today that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen's R&D efforts on challenging integral membrane protein targets. Financial details were not disclosed. "This exciting new collaboration aims at tackling some of the unique challenges that have limited the success of discovering and developing drugs targeting complex membrane proteins," said Mauro Mileni, CEO of Abilita Bio. "Amgen helped define the field of biotechnology and has driven innovation through outstanding science. We look forward to working with their exceptional research teams to drive tough projects forward." About the EMP™ technology platform About Abilita Bio, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/abilita-bio-and-amgen-enter-into-a-multi-target-collaboration-300794757.html SOURCE Abilita Bio, Inc. |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |